Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range450.00 - 5,400.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪20.54M
Enterprise Value8.26B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.47
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.65
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance-sheet FlexibilityVery low debt materially reduces near-term bankruptcy and interest-rate risk, preserving strategic optionality. For a clinical-stage biotech this balance-sheet strength supports continued R&D or partnering without immediate solvent distress, enabling staged financing or non-dilutive deals.
Veterinary Partner-funded Development And LicensingA partner-funded Phase 2 and an exercised licensing option structurally de-risks the piclidenoson veterinary program. Upfront, milestone and royalty economics materially reduce the company's direct cash burn and create a non-dilutive potential revenue stream over the coming decade if development succeeds.
Intellectual Property Build For NamodenosonAn allowed patent strengthens exclusivity for a nascent anti-obesity franchise, increasing long-term commercialization and licensing optionality. Durable IP coverage enhances bargaining power with partners and supports future royalty streams or franchise monetization if clinical development advances.
Bears Say
Shrinking Revenue And Worsening Operating LossesRevenue declined materially (2025 down ~22%) while operating losses widened, showing the business is not scaling toward self-sustaining commercialization. Persistent losses far exceeding tiny revenue indicate structural profitability challenges absent successful product launches or licensing exits.
Consistently Negative Operating And Free Cash FlowMulti-year negative operating and free cash flow demonstrates chronic cash burn. Although FCF improved in 2025 versus 2024, the company still consumes significant cash annually, forcing reliance on external capital or partners to fund clinical programs and limiting long-term independence.
Equity Volatility And Dependence On External FundingMaterial equity fluctuations and sharply negative returns indicate the company has repeatedly needed outside capital. Continued clinical-stage spending without positive cash generation makes future dilutive financing or deal-dependent strategies likely, constraining strategic flexibility and investor returns.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 450.00 and its highest was 5400.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪20.54M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 129 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -18.647 earnings per share for the quarter, beating the consensus estimate of -20.719 by 2.072.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -18.647 in its last earnings report, beating expectations of -20.719. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.